Glimmers of hope for targeting oncogenic KRAS-G12D

Research output: Contribution to journalEditorialpeer-review


KRAS mutations are one of the most common genetic abnormalities in cancer, especially lung, colon, and pancreatic cancers. Strategies targeting the oncogenic KRAS pathway include direct and indirect approaches. KRAS-G12C inhibitors developed based on binding to the switch II pocket structure of KRAS mutant protein represent a breakthrough in the development of targeted therapeutic strategies against oncogenic proteins previously considered undruggable. The covalent KRAS-G12C inhibitors sotorasib (AMG510) and adagrasib (MRTX849) are used to treat patients with KRAS-G12C-mutated non-small cell lung cancer. Emerging research shows that other host point mutations in KRAS can also be directly targeted by small-molecule compounds. Recently, through extensive structure-based drug design from Mirati Therapeutics, a novel non-covalent KRAS-G12D inhibitor, MRTX1133, showed significant preclinical antitumor activity in KRAS-G12D-bearing tumor cells, especially pancreatic ductal adenocarcinoma. Here, we discuss the selectivity, efficacy, toxicity, and potential application challenges of this novel targeted protein inhibitor.

Original languageEnglish (US)
Pages (from-to)391-393
Number of pages3
JournalCancer Gene Therapy
Issue number3
StatePublished - Mar 2023

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Cancer Research


Dive into the research topics of 'Glimmers of hope for targeting oncogenic KRAS-G12D'. Together they form a unique fingerprint.

Cite this